Scholarlink

<p>Fragment-based drug discovery (FBDD) uses small molecular fragments as starting points for drug development, and machine-learning models that operate on molecular string representations are increasingly applied to fragment-related tasks. SMILES is the dominant such representation, but its paired ring closures and balanced parentheses introduce syntactic complexity that can affect model behavior. We present a controlled study of how molecular string representation influences transformer-based fragment recovery, using an FBDD-motivated label pipeline: reference fragments are derived from known drugs via RECAP fragmentation and docking-based ranking, and the model is scored on recovering them. We introduce DeepBERTa, a ChemBERTa-derived transformer pretrained on DeepSMILES, and evaluate it against a matched SMILES baseline under identical architecture, data splits, and optimization (approximately 34,000 drug–fragment pairs). DeepSMILES produces syntactically valid predictions more often than SMILES (54.2% vs. 43.5%) and a higher full test-set mean Tanimoto similarity (0.36 vs. 0.29). A per-sample selection between the two representations raises mean Tanimoto to 0.43, and a deployable variant that selects on model confidence rather than the reference recovers most of this gain. Among molecules where one representation strictly wins, DeepSMILES wins more often than SMILES (27.8% vs. 16.3% of test molecules). These results show that string representation meaningfully influences transformer fragment recovery and that representation-aware selection outperforms either representation alone.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Transformer-based molecular fragment prediction using SMILES and DeepSMILES representations in a fragment-based drug discovery pipeline

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月31日

查看全文
  • Aayush Kothari,
  • Amish Gupta,
  • Nisarg Shah,
  • Thomas Reed,
  • Anvita Nattuva,
  • Rahima Nazirudeen,
  • Harman Brah,
  • Marx Akl

摘要

Fragment-based drug discovery (FBDD) uses small molecular fragments as starting points for drug development, and machine-learning models that operate on molecular string representations are increasingly applied to fragment-related tasks. SMILES is the dominant such representation, but its paired ring closures and balanced parentheses introduce syntactic complexity that can affect model behavior. We present a controlled study of how molecular string representation influences transformer-based fragment recovery, using an FBDD-motivated label pipeline: reference fragments are derived from known drugs via RECAP fragmentation and docking-based ranking, and the model is scored on recovering them. We introduce DeepBERTa, a ChemBERTa-derived transformer pretrained on DeepSMILES, and evaluate it against a matched SMILES baseline under identical architecture, data splits, and optimization (approximately 34,000 drug–fragment pairs). DeepSMILES produces syntactically valid predictions more often than SMILES (54.2% vs. 43.5%) and a higher full test-set mean Tanimoto similarity (0.36 vs. 0.29). A per-sample selection between the two representations raises mean Tanimoto to 0.43, and a deployable variant that selects on model confidence rather than the reference recovers most of this gain. Among molecules where one representation strictly wins, DeepSMILES wins more often than SMILES (27.8% vs. 16.3% of test molecules). These results show that string representation meaningfully influences transformer fragment recovery and that representation-aware selection outperforms either representation alone.